FDA labs stay open
This article was originally published in The Tan Sheet
Executive Summary
House Energy and Commerce Chairman John Dingell says an Aug. 17 decision by FDA to not proceed with reorganization plans that include closing seven of its field labs will maintain an "essential part of protecting consumers and ensuring the safety of our nation's food and drug supply." FDA has called off plans to close seven of its 13 labs as part of the Office of Regulatory Affairs reorganization it announced in March, Dingell and fellow Michigan Democrat Bart Stupak, Oversight and Investigation Subcommittee chairman, say in a release (1"The Tan Sheet" March 26, 2007, p. 5). The House has passed legislation with FDA's fiscal 2008 appropriations with an amendment from Stupak that prohibits the agency from using any of the funding to pay for closing its field labs or ORA district offices...
You may also be interested in...
FDA To Close Regional Offices, Consolidate Districts Under ORA Reorg
FDA's decision to reorganize the Office of Regulatory Affairs will cause a "slow motion effect" for industry's interaction with FDA, according to a dietary supplement trade group executive
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.